Ribomic Confident in Efficacy Outcome of Upcoming PII of Wet-AMD Treatment with Just 40 Patients: Pres.

Ribomic President Yoshikazu Nakamura Yoshikazu Nakamura, president of Ribomic, a nucleic acid drug discovery upstart originated from the University of Tokyo, predicted on May 16 that the company’s investigational anti-FGF2 aptamer RBM-007 will be able to demonstrate its efficacy even...read more